No abstract

No abstract

Günlük uygulamada ayaktan tedavi gören bir ergen hasta popülasyonunda aripiprazolün etkinlik ve tolerabilitesi Amaç: Ayaktan tedavi edilen ergen hastalarda aripiprazolün endikasyon dışı kullanım özelliklerini belirlemek ve geniş bir yelpazede ruhsal belirti ve bozukluk gösteren ergenlerin tedavisinde aripiprazolün etkinliğini ve tolerabilitesini saptamaktır. Yöntem: Hasta dosyaları geriye dönük kayıt taraması yöntemiyle değerlendirilmiştir. Klinik Global izlenim (KGİ) ölçekleri, Kısa Semptom Envanteri (KSE) ve Extrapyramidal Belirtileri Değerlendirme Ölçeği kullanılmıştır. Bulgular: Otuz bir hastanın verisine ulaşıldı. Örneklemin çoğu kız hastadan oluşmaktadır (%87.1). Ortalama yaş 16.38±1.14'dir ve 15-19 yaş arasındadır. Hastaların %67,8'inin en az bir komorbid bozukluğu vardır. En sık komorbid bozukluk, major depresif bozukluktur. Aripiprazolün ortalama başlangıç dozu 4.83±3.59 mg'dır (ranj:2,5-20 mg/ gün) ve son vizitteki ortalama doz 8.62±3.46 mg'dır. (ranj:2,5-15 mg/ gün). Ortalama aripiprazol tedavi süresi 19.56±1.23 aydır (ranj:4-48 ay). Son vizit KGİ şiddet puanları, başlangıç puanlarına göre anlamlı derecede daha düşüktür (p<0.001).

Research on areas such as social cognition, autistic traits, and minor physical anomalies in comorbid Specific Learning Disorder (SLD) and attention-deficit/hyperactivity disorder (ADHD) is limited. In this study, we compared these areas in children aged between 8 and 14 with comorbid SLD and ADHD and their typically developed peers. Emotion recognition and social cognition were evaluated by Faces Test, Reading the Mind in the Eyes Test, Comprehension Test, and Difficulties in Emotion Regulation Scale. Autism Spectrum Screening Questionnaire and Social Responsiveness Scale were used for screening of autism spectrum disorder in children. Furthermore, autistic traits in parents were measured by Autism-Spectrum Quotient. The MPAs of all the subjects were determined by pediatric geneticists. We detected that children with comorbid SLD and ADHD performed worse than controls in all social cognition tests and maternal AQ score had a strong correlation with the Faces Test, DERS, and SRS scores. Also, the total ASSQ score in the comorbid SLD and ADHD group was significantly higher than controls. Finally, MPAs were significantly more frequent in the comorbid SLD and ADHD group. Impairment in social cognition and evaluation of autistic traits and dysmorphology in children with comorbid SLD and ADHD may provide useful information on neurodevelopmental disorders.

Objectives: Schizophrenia is a disorder with different clinical features. Schizophrenia may start insidiously and slow and go on for many years. But the negative symptoms and deficiency symptoms leading to social deterioration may come to the forefront. All these factors are taken into consideration, our aim in this study was to examine the demographic and clinical effects of symptoms on schizophrenic patients who have not yet been treated. Methods: Eighty patients who were admitted to the Ankara Numune Training and Research Hospital Psychiatry Outpatient Clinic, who did not have any previous antipsychotic medications and who did not use medications at the time of admission and who met the criteria for schizophrenia according to the DSM-5. Sociodemografic Data Form and the PANSS scale were used to assess the clinical status of the patients. Results: When the demographic characteristics of the participants were examined, 33 (41.2%) were female and 47 (58.8%) were male. The mean age of the patients was 31.08±9.37; mean education year was 8.76±3.53. When the patients participating in the study were evaluated in terms of gender, marital status, working status, smoking status, and family history, no statistical differences were found between the groups in terms of their PANSS scores (p>0.05). However, the PANSS Negative subscale scores (p<.001), general psychopathology scores (p=0.006), and total PANSS scores (p=0.003) were statistically significantly different between the three groups when the patients were untreated for 0-1 years, 1-5 years, and 5 years. Conclusions: In this study none of the sociodemographic factors we assessed had any effect on symptom severity. However, there are different results in the literature regarding gender, age, marital status and working status. Besides, it has been determined that the most important clinical manifestation in our study is the period without treatment. Further studies should identify demographic and clinical features that affect schizophrenic symptom changes.